Concomitant angiosarcoma and lymphoproliferative disorder in solid organ transplant recipients
© Baer et al.; licensee BioMed Central Ltd. 2014
Received: 30 September 2014
Accepted: 13 October 2014
Published: 31 October 2014
An increased risk of posttransplant malignancy has been consistently reported following various solid organ transplants. The malignancies most commonly encountered are non-melanoma skin cancers, carcinomas of lung or breast and posttransplant lymphoproliferative disorders. Angiosarcoma, an uncommon vascular mesenchymal neoplasm, is rare in the posttransplant setting. This report describes two patients who developed high-grade angiosarcoma following a solid organ transplant. Notably, in both patients, the diagnosis of angiosarcoma was preceded by diagnosis of a lymphoproliferative disorder with monoclonal immunoglobulin heavy chain rearrangement.
KeywordsAngiosarcoma Posttransplant lymphoproliferative disorder Solid organ transplant
An increased risk of developing malignancy has been observed following solid organ transplantation, with rates and malignancy type closely related to the transplanted organ. The most common neoplasms encountered are non-melanoma skin cancers (NMSC). Significant increases in incidence of other common malignancies such as lung, breast, and renal cell carcinomas are consistently reported as well. While posttransplant lymphoproliferative disorder (PTLD) is one of the more common malignancies developing in solid organ transplant recipient, angiosarcoma is rare in this setting. We describe two patients diagnosed with concomitant PTLD and angiosarcoma following solid organ transplant.
A 25-year-old female with a prolonged history of gastroparesis secondary to intestinal neuronal dysplasia. After presenting with intestinal pseudo-obstruction in May 2006, she underwent multiple surgical interventions, including a partial colectomy, lysis of adhesions, resection of ilieo-colic anastomosis, and repeat ilieo-colic anastomosis. In March 2009, she presented with intestinal dysmotility and liver failure, ultimately undergoing multi-visceral transplantation (en bloc transplant of stomach, pancreas, liver, small bowel, and colon). Following the transplant, she was maintained on rapamycin for immunosuppression. EBV DNA copies were not detected prior to transplant but quickly rose to 3,500 copies following transplant and upon initiation of immune suppression. Her viral level became undetectable on anti-viral therapy.In September 2012, she had a colostomy surgery due to abdominal distention and colonic dysmotility. At the same time, an enlarged left cervical node was noted, and a biopsy was performed. Pathology review of the specimen showed a focal increase in large B cell population, found to be distributed in loose nodules concerning for PTLD. Flow cytometry was attempted but failed due to the low cellularity of the specimen. However, a clonal immunoglobulin heavy chain gene rearrangement was detected by PCR, further supporting the possibility of PTLD. In November 2012, the patient noted rapidly increasing abdominal girth. CT imaging demonstrated ascites and a 4.8cm ill-defined soft tissue density in the left suprarenal area. In January 2013, she underwent resection of the left adrenal mass, a mass around the splenic bed, and of an abdominal deposit. Pathology of these areas showed high-grade angiosarcoma with positive surgical margins (Figure 1C). Immunohistochemical stains were positive for CD34, CD31 (Figure 1D), CAN5.2, factor VIII, c-KIT and inhibin. HHV-8 immunostaining of the tumor was negative. Post-surgical CT scan on 2/2013 showed no evidence of residual disease. The hospital course was further complicated by rejection, treated with anti-thymocyte globulins (ATG) and steroids. Her condition continued to worsen with dyspnea and new inferior vena caval and peroneal venous thrombosis. The patient and family opted for palliative care, and she passed away prior to systemic therapy.
An increased risk of developing malignancy has been consistently observed following solid organ transplantation, with rates and malignancy type varying on the transplanted organ. Non-melanoma skin cancers (NMSCs) are the most common malignancy in transplant recipients and affect up to 10-45% of transplant recipients, depending on race and ultraviolet light exposure. Squamous cell carcinoma is the most common NMSC. Recipients of renal transplants, the most common solid organ to be transplanted, are the best studied to date in the context of post-transplant malignancies. In renal transplant recipients, the incidences of the most common cancers (colon, lung, prostate and breast) are roughly two-fold higher in the first 3 years after kidney transplantation, when compared to the general population. Kaposi’s sarcoma and non-Hodgkin’s lymphoma are more than 20-fold higher than in the general population. When compared to patients on transplant waiting lists, several malignancies rates are more common: NMSCs (2.6-fold), melanoma (2.2-fold), Kaposi’s sarcoma (9.0-fold) and non-Hodgkin’s lymphoma (3.3-fold). Angiosarcoma is not reported as a unique entity in these studies and is included in the non-skin malignancies not otherwise specified (NOS) category which accounts for about 3% of the malignancies developing in the first 3 years following kidney transplant.
The relative rate of each post-transplant malignancy varies depending on the transplanted solid organ. In 2011, the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients reported a 2% incidence of PTLD at 5 years post renal-transplant in EBV-negative adult recipients. Following liver transplant, the rate of PTLD is 10.2% at 5 years, with slightly higher rates in EBV-negative recipients. In contrast, PTLD following heart transplant is relatively infrequent in adult recipients and closely linked to EBV status. Risk of malignancy of any kind is especially high following lung transplant and has been reported to be as high as 15.4% at 5 years post-transplant. These observed differences in risk may be due to variations in length and type of immunosuppression given to recipients of the various solid organs.
Immunosuppression is often cited as the etiology of the increased risk of malignancy, possibly by conferring susceptibility to viruses implicated in oncogenesis such as EBV, herpes simplex, herpes zoster, HHV8 and polyoma virus. Other potential mechanisms include direct oncogenesis by the immunosuppressive agents themselves; for example, the chromosome breaks and nuclear abnormalities observed with azathioprine use. Hepatic angiosarcoma developing following an extensive cyclophosphamide exposure was reported in a patient treated for polyarteritis nodosa. In kidney transplant recipients, immunosuppression with cyclosporine did not confer added risk when compared with azathioprine/steroid treatment, whereas treatment with tacrolimus has been shown to increase the risk approximately two-fold. Induction or anti-rejection therapy with OKT3 or ATG increases the risk of lymphoma during the first post-transplant year.
Sarcomas are uncommon mesenchymal malignancies and comprise less than 1% of malignant neoplasms in adults. 80% of them arise in soft tissues[8, 9]. Angiosarcoma is an uncommon type of soft tissue sarcoma, which may rise in a variety of tissues or organs. A well-documented risk factor for developing angiosarcoma is therapeutic radiation, such as the risk observed 8–10 years after breast radiotherapy. Angiosarcoma has a propensity for early metastases and often presents with an aggressive biologic behavior. In a series of 67 patients with angiosarcomas, the actuarial 5 year disease-free-survival is 35% and the 5 year overall survival is 24%. In another series of 82 patients with angiosarcoma, the five-year disease-specific survival is found to be 60%, with negative prognostic variables including higher tumor grade and tumors arising in areas of lymphedema or prior irradiation. Similar to the majority of soft tissue sarcomas, the mainstay of therapy is complete surgical resection of the tumor, if operable. Adjuvant therapies such as post-operative radiation to the tumor bed with wide margins are offered to patients with tumors larger than 5cm or to those with positive surgical margins. The role of adjuvant chemotherapy remains controversial in soft tissue sarcoma due to lack of consistent survival benefit in studies published to date. Newer studies evaluating paclitaxel and bevacizumab in patients with unresectable or metastatic angiosarcoma suggest a possible role for these to treat angiosarcoma[13, 14].
Post-transplant angiosarcomas are rare and, to date, have been reported in less than 20 solid organ transplant recipients. In a single-institution prospective database encompassing 1,570 liver transplantations in 1,421 patients from 1985 to 1999, 125 patients (8.8%) developed de novo tumors, one of them being angiosarcoma. The majority of reported patients with post-transplant angiosarcoma have been renal transplant recipients with tumor frequently developing at the site of a previously placed arterio-venous fistula. An association has been suggested between angiosarcoma and oncoviruses, such as HHV-8, following detection of a viral sequence in the DNA of a primary angiosarcoma. This association remains controversial, as others have failed to detect similar sequences in either primary or in post-transplant angiosarcoma. In a series of 3 patients with PTLD reported by Webster et al., 2 of the patients have PTLD as well as angiosarcoma. In this series, 1 patient has been identified with an EBV-positive tumor and a second with an elevated EBV titer at the time of diagnosis of disseminated angiosarcoma. The 2 patients in our paper both had angiosarcomas diagnosed following a prior diagnosis of PTLD, and 1 had a positive EBV titer detected at the time of angiosarcoma diagnosis. Both angiosarcomas were found to be negative for HHV-8 immunostaining.
In summary, the few reported patients with angiosarcoma and PTLD vary in type of transplanted organ, immunosuppression therapy and in seropositivity for a possible oncogenic virus. While the possible association of the rare post-transplant angiosarcomas with PTLD may suggest the presence of underlying host variables predisposing the recipients to develop post-transplant malignancies, these are yet to be defined. Assessment of genetic abnormalities in these tumors in the future may inform the possible susceptibility conferring host variables.
Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Posttransplant lymphoproliferative disorder
Soft tissue sarcoma
Magnetic resonance imaging
Positron emission tomography
Polymerase chain reaction
Non-melanoma skin cancers.
This publication was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Number KL2 TR000081. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
- Zafar SY, Howell DN, Gockerman JP: Malignancy after solid organ transplantation: an overview. Oncologist. 2008, 13: 769-778. 10.1634/theoncologist.2007-0251View ArticlePubMedGoogle Scholar
- Kasiske BL, Snyder JJ, Gilbertson DT, Wang C: Cancer after kidney transplantation in the United States. Am J Transplant. 2004, 4: 905-913. 10.1111/j.1600-6143.2004.00450.xView ArticlePubMedGoogle Scholar
- Recipients USDoHHSTUSOPaTNatSRoT: 2006 OPTN/SRTR Annual Report: Transplant Data 1996–2005. 2006, http://optn.transplant.hrsa.gov 2007,Google Scholar
- Sheil AG: Cancer in immune-suppressed organ transplant recipients: aetiology and evolution. Transplant Proc. 1998, 30: 2055-2057. 10.1016/S0041-1345(98)00539-9View ArticlePubMedGoogle Scholar
- Jensen MK: Chromosome studies in patients treated with azathioprine and amethopterin. Acta Med Scand. 1967, 182: 445-455.View ArticlePubMedGoogle Scholar
- Rosenthal AK, Klausmeier M, Cronin ME, McLaughlin JK: Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature. Am J Clin Oncol. 2000, 23: 581-583. 10.1097/00000421-200012000-00010View ArticlePubMedGoogle Scholar
- Gutierrez-Dalmau A, Campistol JM: Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs. 2007, 67: 1167-1198. 10.2165/00003495-200767080-00006View ArticlePubMedGoogle Scholar
- Mark RJ, Poen JC, Tran LM, Fu YS, Juillard GF: Angiosarcoma. A report of 67 patients and a review of the literature. Cancer. 1996, 77: 2400-2406. 10.1002/(SICI)1097-0142(19960601)77:11<2400::AID-CNCR32>3.0.CO;2-ZView ArticlePubMedGoogle Scholar
- Abraham JA, Hornicek FJ, Kaufman AM, Harmon DC, Springfield DS, Raskin KA, Mankin HJ, Kirsch DG, Rosenberg AE, Nielsen GP, Desphpande V, Suit HD, DeLaney TF, Yoon SS: Treatment and outcome of 82 patients with angiosarcoma. Ann Surg Oncol. 2007, 14: 1953-1967. 10.1245/s10434-006-9335-yView ArticlePubMedGoogle Scholar
- Tahir M, Hendry P, Baird L, Qureshi NA, Ritchie D, Whitford P: Radiation induced angiosarcoma a sequela of radiotherapy for breast cancer following conservative surgery. Int Semin Surg Oncol. 2006, 3: 26- 10.1186/1477-7800-3-26PubMed CentralView ArticlePubMedGoogle Scholar
- Ward JR, Feigenberg SJ, Mendenhall NP, Marcus RB, Mendenhall WM: Radiation therapy for angiosarcoma. Head Neck. 2003, 25: 873-878. 10.1002/hed.10276View ArticlePubMedGoogle Scholar
- Sarcoma Meta-analysis Collaboration: Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet. 1997, 350: 1647-1654.View ArticleGoogle Scholar
- Agulnik M, Yarber JL, Okuno SH, von Mehren M, Jovanovic BD, Brockstein BE, Evens AM, Benjamin RS: An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Ann Oncol. 2013, 24: 257-263. 10.1093/annonc/mds237View ArticlePubMedGoogle Scholar
- Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JE: Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008, 26: 5269-5274. 10.1200/JCO.2008.17.3146View ArticlePubMedGoogle Scholar
- Sanchez EQ, Marubashi S, Jung G, Levy MF, Goldstein RM, Molmenti EP, Fasola CG, Gonwa TA, Jennings LW, Brooks BK, Klintmalm GB: De novo tumors after liver transplantation: a single-institution experience. Liver Transpl. 2002, 8: 285-291. 10.1053/jlts.2002.29350View ArticlePubMedGoogle Scholar
- Webster P, Wujanto L, Fisher C, Walker M, Ramakrishnan R, Naresh K, Thomas JM, Papalois V, Crane J, Taube D, Duncan N: Malignancies confined to disused arteriovenous fistulae in renal transplant patients: an important differential diagnosis. Am J Nephrol. 2011, 34: 42-48. 10.1159/000328908View ArticlePubMedGoogle Scholar
- Gyulai R, Kemeny L, Kiss M, Nagy S, Adam E, Nagy F, Dobozy A: Human herpesvirus 8 DNA sequences in angiosarcoma of the face. Br J Dermatol. 1997, 137: 467- 10.1111/j.1365-2133.1997.tb03761.xView ArticlePubMedGoogle Scholar
- Lebbe C, Pellet C, Flageul B, Sastre X, Avril MF, Bonvalet D, Morel P, Calvo F: Sequences of human herpesvirus 8 are not detected in various non-Kaposi sarcoma vascular lesions. Arch Dermatol. 1997, 133: 919-920. 10.1001/archderm.1997.03890430141027View ArticlePubMedGoogle Scholar
- Lebbe C, Tatoud R, Morel P, Calvo F, Euvrard S, Kanitakis J, Faure M, Claudy A: Human herpesvirus 8 sequences are not detected in epithelial tumors from patients receiving transplants. Arch Dermatol. 1997, 133: 111-PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.